NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) investors concerning whether the company’s officers and board of directors violated their fiduciary duties.
On June 19, 2014 shares of the Company fell $2.06, or 22.97%, during intraday trading after a report featured on TheStreet.com stated, “The prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct.” MD Anderson Cancer Center is running the DCVax-Direct clinical trial with funding from Northwest Biotherapeutics. According to the report, investigators at MD Anderson, one of several sites conducting the study, have not yet been able to analyze data collected because patients are still being enrolled and treated in the study.
If you are a Northwest Biotherapeutics, Inc. stockholder and have information that could assist in this investigation, please contact J. Brandon Walker, Esq. by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.